Striatech Leads Ethical Vision Research at FELASA 2025
Striatech, a pioneer in non-invasive vision research technologies, will showcase its latest advancements at the FELASA 2025 Congress in Athens,
Read moreStriatech, a pioneer in non-invasive vision research technologies, will showcase its latest advancements at the FELASA 2025 Congress in Athens,
Read moreBioMarin Pharmaceutical Inc. has entered into a definitive agreement to acquire clinical-stage biotech Inozyme Pharma, Inc. for approximately $270 million
Read moreIn a strategic move to expand its oncology pipeline, GSK plc (LSE/NYSE: GSK) announced on Tuesday, it has entered into
Read moreGlobal biopharmaceutical leader AstraZeneca has officially opened a new $300 million state-of-the-art cell therapy manufacturing facility in Rockville, Maryland, marking
Read moreA research study has showcased the use of Cellendes’ advanced 3-D Life Hydrogel products in developing an immunocompetent, PDMS-free organ-on-chip
Read moreThe unique OptoDrum device for automated in vivo assessment of visual performance in mice and rats offers unmatched capabilities for
Read moreAccelerating Immunoassay Development With Automated Storage, Filling and Labeling – Case Study An HTI Automation & Mabtech Case Study The
Read moreAt Striatech, advancing the future of ophthalmic research is a central commitment. In partnership with the ARVO Foundation for Eye
Read moreMerck KGaA is moving forward with the acquisition of SpringWorks Therapeutics, confirming a definitive agreement at $47 per share in
Read moreEli Lilly and Company announced groundbreaking Phase 2 results for its investigational siRNA therapy lepodisiran, which reduced lipoprotein(a) [Lp(a)] levels
Read more